logo

For the Inventor, By the Inventor

Wilmington, DE, United States of America

Incyte Corporation


USPTO Granted Patents = 686

% Expired Patents = 11.5



Trademarks = 7

Forward Citations = 10,431

Loading Chart...
Loading Chart...

390 inventors (with patents filed for the assignee):

goldMedal Wenqing Yao (223 out of 228 patents)

silverMedal Andrew Paul Combs (115 out of 128 patents)

bronzeMedal Liangxing Wu (114 out of 114 patents)

4.  Yun-Long Li (89 out of 96 patents)

5.  Jincong Zhuo (71 out of 76 patents)

6.  Chunhong He (71 out of 73 patents)

7.  Jiacheng Zhou (63 out of 86 patents)

8.  Richard B Sparks (63 out of 64 patents)

9.  Eddy W Yue (62 out of 69 patents)

10.  James David Rodgers (62 out of 86 patents)

11.  Stacey Shepard (57 out of 59 patents)

12.  Brian Walter Metcalf (55 out of 87 patents)

13.  Xiaozhao Wang (49 out of 51 patents)

14.  Ding-Quan Qian (49 out of 49 patents)

15.  Zhongjiang Jia (48 out of 49 patents)


Core Competencies:
JAK Inhibitors
FGFR Inhibitors
KRAS Inhibitors
Immunomodulators
Tetracyclic Compounds
Tricyclic Compounds
Biomarkers
Combination Therapy
Pharmaceutical Formulations
PI3K Inhibitors
Anti-PD-1 Antibodies
Solid Forms

686 patents:

1. 12735424 - Fused pyrazine derivatives as A2A / A2B inhibitors (2026-09-15),
2. 12692276 - Tricyclic triazolo compounds as DGK inhibitors (2026-07-28),
3. 12643881 - BICYCLIC AMINE CDK12 INHIBITORS (2026-06-02),
4. 12642802 - Topical formulations of ruxolitinib with an organic amine pH adjusting agent for treatment of skin diseases (2026-06-02),
5. 12622908 - Topical formulation for a JAK inhibitor (2026-05-12),
6. 12600723 - Tetracyclic compounds as DGK inhibitors (2026-04-14),
7. 12600722 - Tetracyclic compounds as DGK inhibitors (2026-04-14),
8. 12600717 - Tricyclic compounds as inhibitors of KRAS (2026-04-14),
9. 12589096 - Ruxolitinib formulation for reduction of itch in atopic dermatitis (2026-03-31),
10. 12564593 - Topical formulation for a JAK inhibitor (2026-03-03),
11. 12552804 - TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS (2026-02-17),
12. 12552792 - SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME (2026-02-17),
13. 12551485 - Topical formulations of ruxolitinib with an organic amine pH adjusting agent for treatment of skin diseases (2026-02-17),
14. 12544381 - Topical formulation for JAK inhibitor (2026-02-10),
15. 12534463 - SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS (2026-01-27),
Incyte is a global biopharmaceutical company that is focused on discovering, developing, and delivering innovative medicines to patients with cancer. They work towards advancing health outcomes and improving the lives of patients through their research and development efforts. Incyte is dedicated to discovering breakthrough treatments through their expertise in molecular biology, functional genomics, medicinal chemistry, and clinical development. With a diverse portfolio of investigational and approved therapies, Incyte strives to make a positive impact on the lives of patients worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Incyte Corporation
686 Patents

#12 in Wilmington, DE

#13 in Delaware

#733 in US

#1,454 in the World

Wilmington, DE (US)
Wilmington, DE, United States of America

Incyte Corporation

Forward Citations = 10,431

390 inventors:

goldMedal Wenqing Yao (223 out of 228 patents)

silverMedal Andrew Paul Combs (115 out of 128 patents)

bronzeMedal Liangxing Wu (114 out of 114 patents)

4.  Yun-Long Li (89 out of 96 patents)

5.  Jincong Zhuo (71 out of 76 patents)

Please report any incorrect information to [email protected]
Loading…